Nucleus Genomics

Nucleus Genomics is releasing Vitruvian, a set of scoring models that rank embryos created through IVF against genetic predictions for traits and disease risk. The company frames this launch as a step beyond its earlier consumer genome reports, extending polygenic scoring from adults into embryo selection for prospective parents working with fertility clinics. The headline claim is that Vitruvian's intelligence model can optimize embryo DNA for 14 IQ points, nearly a standard deviation , a figure that describes the projected gap between the highest and lowest scoring embryo in a typical IVF batch rather than any change to the DNA itself. The models were trained on more than 1,000,000 people, validated across 40,000+ siblings, and use more than 7 million genetic markers , with within-family validation being the standard method for separating genetic signal from shared environment in this kind of prediction. Nucleus partnered with established embryo screening company Genomic Prediction to bring the software to market , and the product sits alongside a higher-touch service in which Sadeghi's team helps customers find a genetically optimal egg or sperm donor, surrogate, and embryo . The launch matters because polygenic embryo selection is moving from research papers into a directly marketed consumer offering, with all the clinical, regulatory, and ethical questions that shift raises. The company was founded by Kian Sadeghi in 2020, when he was 20 , and got its start analyzing genomes to weigh a person's risk of everything from cancer to ADHD before expanding into embryo analysis. Founders, investors, and operators evaluating this launch should read it in the context of an active debate, as earlier Nucleus products have drawn criticism from researchers who have raised the alarm about the scientific claims and the framing around trait selection.